January 3, 2018 / 12:37 PM / 5 months ago

BRIEF-Sangamo And Pfizer Announce Collaboration For Development Of Zinc Finger Protein Gene Therapy For Als

Jan 3 (Reuters) - Pfizer Inc:

* SANGAMO AND PFIZER ANNOUNCE COLLABORATION FOR DEVELOPMENT OF ZINC FINGER PROTEIN GENE THERAPY FOR ALS

* SANGAMO THERAPEUTICS​ - CO, ‍PFIZER ANNOUNCED COLLABORATION FOR DEVELOPMENT OF ZINC FINGER PROTEIN GENE THERAPY FOR ALS

* SANGAMO THERAPEUTICS INC - UNDER TERMS OF COLLABORATION AGREEMENT, SANGAMO WILL RECEIVE A $12 MILLION UPFRONT PAYMENT FROM PFIZER

* SANGAMO THERAPEUTICS INC - UNDER AGREEMENT, CO ‍WILL BE RESPONSIBLE FOR DEVELOPMENT OF ZFP-TF CANDIDATES​

* SANGAMO - UNDER TERMS ELIGIBLE TO RECEIVE POTENTIAL DEVELOPMENT & COMMERCIAL MILESTONE PAYMENTS UP TO $150 MILLION, TIERED ROYALTIES ON NET SALES

* SANGAMO - UNDER DEAL,‍PFIZER OPERATIONALLY,FINANCIALLY RESPONSIBLE FOR RESEARCH,DEVELOPMENT,COMMERCIALIZATION FOR C9ORF72 ZFP-TF,RESULTING PRODUCTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below